Beacon Diagnostics Inc., Centocor deal

Beacon received exclusive worldwide rights to use CNTO's tumor markers to develop saliva-based diagnostics to detect gastrointestinal, prostate, breast and ovarian cancers. The markers include CA 19-9 and CA 72-4 for gastrointestinal cancers; Prostate Specific Antigen (PSA) for prostate cancer; CA 15-3 for breast cancer; and CA1 125 for ovarian cancer. ...